Alere Inc. (ALR) Shares Bought by Vanguard Group Inc.
Vanguard Group Inc. boosted its stake in shares of Alere Inc. (NYSE:ALR) by 0.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,006,208 shares of the medical research company’s stock after buying an additional 64,046 shares during the quarter. Vanguard Group Inc. owned approximately 8.02% of Alere worth $351,641,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Cowen Inc. lifted its holdings in Alere by 1,232.5% during the 2nd quarter. Cowen Inc. now owns 1,361,342 shares of the medical research company’s stock valued at $68,326,000 after buying an additional 1,259,181 shares in the last quarter. Gabelli Funds LLC lifted its holdings in Alere by 1.3% during the 2nd quarter. Gabelli Funds LLC now owns 1,068,238 shares of the medical research company’s stock valued at $53,615,000 after buying an additional 13,865 shares in the last quarter. Omni Partners LLP bought a new stake in Alere during the 2nd quarter valued at about $51,703,000. Goldman Sachs Group Inc. lifted its holdings in Alere by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 763,211 shares of the medical research company’s stock valued at $30,322,000 after buying an additional 16,572 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Alere by 8.2% during the 1st quarter. Geode Capital Management LLC now owns 666,179 shares of the medical research company’s stock valued at $26,466,000 after buying an additional 50,238 shares in the last quarter. Institutional investors own 89.33% of the company’s stock.
ALR has been the subject of a number of research analyst reports. Zacks Investment Research lowered shares of Alere from a “hold” rating to a “sell” rating in a report on Thursday, August 17th. BidaskClub downgraded shares of Alere from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. Finally, Canaccord Genuity reissued a “hold” rating and set a $51.00 target price on shares of Alere in a research report on Tuesday, September 19th. One equities research analyst has rated the stock with a sell rating and six have issued a hold rating to the stock. Alere has an average rating of “Hold” and a consensus price target of $48.00.
Alere Inc. (ALR) opened at 50.99 on Friday. Alere Inc. has a 52-week low of $34.41 and a 52-week high of $51.00. The stock’s market cap is $4.47 billion. The firm’s 50-day moving average is $49.93 and its 200-day moving average is $48.47.
Alere Inc is a provider of health information through diagnostic tests. The Company’s segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus.
Want to see what other hedge funds are holding ALR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alere Inc. (NYSE:ALR).
Receive News & Ratings for Alere Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alere Inc. and related companies with MarketBeat.com's FREE daily email newsletter.